Publication

From Prediction to Decision Making: PBPK and QSP as Regulatory-Grade NAMs

New CPT review by Certara's Karen Rowland Yeo & Piet van der Graaf shows how…

Danielle PillsburySeptember 23, 2026

Publication

Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers

A semi-mechanistic population PK model characterizes sorfequiline and its active M3 metabolite to support DDI…

CertaraSeptember 18, 2026

Publication

Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients

Explore advances in model-informed precision dosing (MIPD) for pediatric antimicrobial therapy, including population PK modeling,…

CertaraJuly 29, 2026

Publication

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…

CertaraFebruary 2, 2026

Publication

Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis

Bridge across studies with Model-based Meta Analysis, incorporating broader data & synthetic patients to enhance…

CertaraOctober 31, 2025

Conference

ICAComP 2025

CertaraOctober 8, 2025

On-Demand Webinar

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…

CertaraJune 18, 2025

Publication

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…

CertaraDecember 9, 2024

Poster

Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis.

CertaraNovember 22, 2024

Blog

Local therapies for the global COVID-19 pandemic

Henri Merdjan explains why topical drug formulations (e.g. intranasal and/or oral) could be valuable as…

CertaraMay 29, 2020

Infectious Disease

From Prediction to Decision Making: PBPK and QSP as Regulatory-Grade NAMs

Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers

Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis

ICAComP 2025

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis.

Local therapies for the global COVID-19 pandemic

Newsletter sign up

Quick links

Solutions

Contact